1. Introduction {#sec1}
===============

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system characterized by demyelination and axonal loss. Signs and symptoms can vary widely throughout the disease course. While sensitive, optic and motor symptoms predominate, other symptomatology can include urinary tract and bowel dysfunction, pain, fatigue, cognitive dysfunction and mood disorders ([@bb001]).

Several case--control studies have established a higher rate of headache in MS population compared to the healthy individuals (HIs) ([@bb002]; [@bb003]; [@bb004]; [@bb005]; [@bb006]). The potential link between MS and migraine has been hypothesized for over 40 years ([@bb007]; [@bb005]). It has been recently shown that MS patients had a three-fold higher frequency of migraine compared to the HIs ([@bb002]). Another most recent meta-analysis found that migraine was more common in 1864 MS patients compared to the 261,563 control subjects, with an odds ratio of 2.6, however there was a heterogeneity between the examined studies ([@bb008]). On the contrary, another German study did not find a higher prevalence of headache or migraine in 491 MS patients compared to 447 controls ([@bb009]).

While the literature supports the idea that MS and migraine are related, the exact mechanism(s) of this association is not well understood ([@bb002]; [@bb003]; [@bb008]; [@bb004]; [@bb005]; [@bb006]). Is migraine simply a comorbidity of MS? Can it signal the onset of MS? If so, what is the underlying pathology? Is it increased frequency related to use of disease-modifying treatment (DMT)? These questions have important implications for diagnosis and treatment of MS and need to be addressed in the future studies. Several studies investigated frequency of migraine in relation to the clinical course of MS and determined that the migraine frequency is increased in patients with relapsing--remitting (RR) MS, whereas the tension-type headache is more frequent in patients with chronic progressive MS ([@bb0010]; [@bb0011]; [@bb0012]; [@bb0013]). A recent case report illustrated a young woman whose initial presentation was that of status migrainosus, after which she developed MS within 2 years ([@bb0014]). The term radiologically isolated syndrome (RIS) has been recently proposed to describe patients with atypical symptoms of MS who present with MRI features suggestive of underlying demyelinating pathology ([@bb0015]). One of the most common complaints in RIS subjects which led to performance of the MRI examination was migraine type headache ([@bb0016]; [@bb0015]). This suggests that migraine can be prominent symptom at early onset of the disease, in addition to have increased comorbidity frequency in RRMS patients.

It has been recently reported in a case study that a patient who had a history of migraine, experienced worsening of migraine-headache symptoms as the initial manifestation of MS, and showed concomitant asymptomatic contrast enhancing (CE) lesions on T1-weighted MRI after gadolinium (Gd) contrast injection ([@bb0017]). This case report raises question, as to the role of CE lesions in the presentation of migraine in MS patients. Our own clinical routine observations prompted us to investigate whether the number and volume of CE lesions are associated to increased frequency of migraine in MS patients. In addition, we aimed to determine if there is relationship between migraine and the presence of other lesion and global and tissue specific brain volume measures in patients with MS.

2. Methods {#sec2}
==========

2.1. Subjects {#sec2.1}
-------------

This study used data from an ongoing prospective study of cardiovascular, genetic and environmental risk factors in MS that enrolled over 1000 patients with clinically isolated syndrome (CIS), MS, other neurological diseases and HIs ([@bb0018]; [@bb0019]; [@bb0020]). The inclusion criteria for this sub-study of migraine in MS were as follows: a) age 18--75 years old, b) having CIS or MS, or being HI and c) MRI examination performed at the time of the clinical visit (±30 days) with standardized 3 T MRI protocol. The exclusion criteria were as follows: a) the presence of a relapse or steroid treatment within 30 days preceding study entry for MS and CIS patients, b) presence of acute headache attack at the time of MRI, c) pre-existing medical conditions known to be associated with brain pathology and d) pregnancy.

Subjects were assessed with structured environmental questionnaire followed by physical and neurological examination. Migraine data were collected from participants in an in-person interview by a trained interviewer, as well as by examination of the patients\' medical records ([@bb0021]). Migraine was defined according to the International Classification of Headache Disorders (ICHD-2) guidelines ([@bb0022]). Subjects who had at least 5 headache attacks in the past that lasted 4--72 h, had at least two of the following characteristics (unilateral location, pulsating quality, moderate or severe pain intensity, aggravation by or causing avoidance of routine physical activity), presence of nausea/vomiting, and were not better accounted by another disorder were classified as migraine headache.

HIs were recruited from hospital personnel, spouses of MS patients or were respondents of local advertisements. By definition HIs were required to have a normal neurological examination and have a normal MRI health screen. Race/ethnicity was determined according to the US Census Bureau definitions.

The study protocol was approved by the local Institutional Review Board and all participants gave their written informed consent.

2.2. MRI acquisition and analysis {#sec2.2}
---------------------------------

All subjects were examined on a 3T GE Signa Excite HD 12.0 Twin Speed 8-channel scanner (General Electric, Milwaukee, WI). MRI sequences included the axial dual fast spin-echo (FSE) T2/PD-weighted image (WI), 3D-spoiled-gradient recalled (SPGR) T1-WI, spin echo (SE) T1-WI pre- and post-contrast, and fluid attenuated inversion recovery (FLAIR) scans. Pulse sequence characteristics for 3 T MRI were as follows: all scans were acquired with a 256 × 256 matrix and a 25.6 cm field of view (FOV) for an in-plane resolution of 1 × 1 mm^2^ with a phase FOV of 75% and one average. Sequence specific parameters were as follows: for the T2/PD-WI: 3-mm-thick slices with no gap, TE1/TE2/TR = 12/95/3000 ms, echo train length = 14, flip angle = 90°; for the FLAIR scans, 3-mm thick slices with no gap, TE/TI/TR = 120/2100/8500 ms, flip angle = 90°; for 3D T1-WI, 1-mm thick slices with no gap, TE/TI/TR = 2.8/900/5.9 ms, flip angle = 10° and for SE T1-WI, 3-mm thick slices with no gap, TE/TR = 16/600 ms, flip angle = 90°. The SE T1-WI sequence was obtained after injection of a single dose intravenous bolus (0.1 mmol/kg gadolinium-DTPA) 5 min after administration of contrast agent only in MS and CIS patients ([@bb0018]; [@bb0023]).

The following MRI measures were collected: CE, T1 and T2 lesion number and lesion volumes (LVs), assessed by a semi-automated edge detection contouring/thresholding technique, as previously reported ([@bb0023]). Measures of brain atrophy included normalized brain volume, normalized gray matter (GM) volume, normalized white matter (WM) volume, normalized cortical volume and normalized lateral ventricle volume ([@bb0018]; [@bb0023]), assessed by the SIENAX 2.6 cross-sectional software tool ([@bb0024]).

2.3. Statistical analysis {#sec2.3}
-------------------------

All data were analyzed using Statistical Package for Social Science (SPSS), version 20.0 (IBM, Armonk, NY). The data were analyzed both by disease group (MS, CIS and HIs) and by MS disease subtype (RR, SP and PP). Differences in demographic and clinical characteristics between subjects with and without migraine were analyzed using chi-square test, Mann--Whitney rank sum test and analysis of variance (ANOVA), as appropriate. In the analysis of covariance (ANCOVA), MRI outcomes were input as the dependent variables, and disease group or MS disease subtype, as the grouping measure with age, gender and DMT status selected as covariates. Given the colinearity between age and disease duration, the latter was not used as covariate.

Additionally, the data were also analyzed using a negative binomial regression given the non-normally distributed lesion data. The inputs into the model included the number of CELs as the dependent measure and migraine status, age, gender and DMT status as the independent variables. Regression analysis was applied to both the disease groups and MS subtypes. The Benjamini--Hochberg correction was used to control the false discovery rate and p-values \< 0.05 were considered significant using two-tailed testing ([@bb0025]).

3. Results {#sec3}
==========

3.1. Demographic and clinical characteristics {#sec3.1}
---------------------------------------------

A total of 826 subjects who fulfilled inclusion and exclusion criteria were selected for this substudy of migraine and MRI. These included 320 patients with RRMS, 124 patients with secondary-progressive (SP) MS, 36 patients with primary-progressive (PP) MS, 64 patients with CIS and 251 HIs. As expected MS patients had higher age, longer disease duration and more advanced disability compared to CIS patients.

[Tables 1 and 2](#t0005 t0010){ref-type="table"} show the differences in the study groups between the subjects with or without migraine. In the MS group there was significantly more females with migraine (p = 0.01). The age of the MS patients with migraine was younger (p = 0.001) and disease duration was shorter (p = 0.024). In the MS disease subtype analyses, the SPMS patients with migraine were younger (p = 0.015), while the PPMS patients with migraine were younger (p = 0.032) and had lower disease duration (p = 0.039). The CIS patients with migraine were younger compared to those without migraine (p = 0.001).

3.2. Frequency of migraine {#sec3.2}
--------------------------

Hundred and thirteen (22.2%) MS patients, 11 (17.2%) of CIS patients and 37 (14.7%) of HIs had migraine (p = 0.067). In the MS disease subtype analyses, patients with RRMS had the highest rate of migraine (24.7%), followed by PPMS (16.7%) and SPMS (16.1%) (p = 0.108).

3.3. MRI differences in subjects with and without migraine {#sec3.3}
----------------------------------------------------------

[Table 3](#t0015){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"} show within disease group differences in subjects with and without migraine. More MS patients with migraine presented with CE lesions compared to those without (35.4% vs. 23.7%, p = 0.013). The mean number of CE lesions in MS patients with migraine was increased respect to those without (0.91 vs. 0.21, p = 0.019). The mean CE-LV was also increased in subjects with migraine respect to those without (125.3 vs. 31.2 mm^3^, p = 0.022). No other MRI lesion and brain volume MRI outcome differences were found in subjects with and without migraine within specific disease groups.

[Table 4](#t0020){ref-type="table"} shows within MS disease subtype study MRI outcome differences in subjects with and without migraine. More RRMS patients with migraine presented with CE lesions compared to those without (41.8% vs. 28.2%, p = 0.035). RRMS patients with migraine had increased mean number of CE lesions (1.19 vs. 0.27, p = 0.023) and CE-LV (164.4 vs. 41.1 mm^3^, p = 0.02) compared to those without. No other MRI lesion and brain volume outcome differences were found in subjects with and without migraine within MS disease subtypes.

3.4. Regression analysis {#sec3.4}
------------------------

Given the non-normally distributed lesion data, we used negative binomial regression to validate the ANCOVA results. MS patients with migraine had increased number of CE lesions (B = 1.242, p = 0.001), but not CE-LV (B = 1.320, p = 0.133) compared to those without migraine. RRMS patients with migraine had increased number of CE lesions (B = 1.377, p = 0.001), but not CE-LV (B = 1.490, p = 0.098) compared to those without migraine.

4. Discussion {#sec4}
=============

This is the largest case--control study to date that investigated the association between migraine and MRI outcomes in MS patients. We found that there is an increased frequency of CE lesions in MS patients with migraine, specifically within the RRMS disease subtype. Given that our clinical/MRI assessments were performed on MS patients with a stable clinical status and in absence of acute headache attack prior to MRI examination, the current findings suggest that having migraine comorbidity may increase level of blood--brain-barrier (BBB) disruption in RRMS patients.

Presence of CE lesions is an indicator of inflammation and breakdown of the BBB, and MRI hallmark for diagnosis and monitoring of MS. Migraine is a disorder characterized by a strong vascular component in which vasoconstriction is followed by vasodilation, mediated by underlying inflammatory cytokines and/or neuropeptides ([@bb0026]). On the other hand, cardiovascular risk factors, including smoking, hypertension, hyperlipidemia, overweight/obesity, diabetes and heart disease are associated with MS ([@bb0018]; [@bb0027]). The pathophysiology of migraine is complex and variety of mediating mechanisms have been proposed including changes in levels of magnesium, calcium and glutamate, as well 5-HT, which stimulates the release of substance P and calcitonin gene related peptide ([@bb0026]). While our study did not assess any one of these factors, our findings do suggest that alterations of the BBB may compromise the microenvironmental vascular regulation. Indeed, previous studies suggested that the pathogenesis of migraine includes an inflammatory component ([@bb0028]). The inflammation of the meninges is an accepted component of the migraine process with release of vasogenic substances such as calcitonin gene-related peptide, substance P, neurokinin A, vasoactive intestinal peptide, and nitric oxide ([@bb0029]). In the last decade, it has been established that highly inflammatory cortical demyelination is also present and common in early MS, topographically associated with prominent meningeal inflammation and may even precede the appearance of classic WM plaques in some MS patients ([@bb0030]). Therefore, future work should explore the association between meningeal inflammation and BBB in MS patients with and without migraine.

In line with previous studies, we found that migraine is present at higher rates in patients with RRMS, compared to those with chronic progressive MS disease subtype ([@bb0010]; [@bb0011]; [@bb0012]; [@bb0013]). These findings are of interest in the context of our results that showed that only RRMS patients had increased number and volume of CE lesions. This may suggest that increased inflammatory component of the disease, usually present in earlier disease stages, may contribute to the development of migraine. However, the present study was not designed to collect information on the temporal relationship between onset of migraine and MS onset. The fact that no association of CE lesions and migraine was found in CIS patients and that frequency of migraine was higher in RRMS vs. CIS in the present study, indicates that migraine may be, at least in part, a comorbidity of MS disease process which is related to more severe BBB damage. A meta-analysis study demonstrated that the number of CE lesions over the first 6 months of follow-up increased the relative risk of relapse occurrence in the subsequent year ([@bb0031]). It has been shown that patients in the relapsing phase have significantly more migraine attacks than those in the remitting phase ([@bb0011]). Indeed, there were no differences in CE lesions in patients with SP and PPMS with and without migraine in the present study. However, it has to be underlined that PPMS patient did not present any CE lesions. While the present study was cross-sectional in design, it will be interesting to monitor the occurrence of CE lesions and migraine attacks in future longitudinal prospective studies using serial MRI.

Several previous MRI studies aimed to establish whether a specific locations of lesions in MS patients is associated with the presence of migraine. One study showed that MS patients with migraine had more lesions in red nucleus, substantia nigra and periaqueductal GM compared to MS patients without migraine ([@bb0032]). Another study confirmed that MS patients who have midbrain plaques, in close proximity to the periaqueductal GM have a four-fold increase in migraines compared to MS patients without plaques ([@bb0033]). These studies aimed to explain the onset of migraine symptoms by interruption of circuits involved in modulating pain pathways. As CE lesions rarely form in those brain areas, the present study poses an alternative hypothesis as to the presence of migraine in MS, by demonstrating that the underlying widespread inflammatory process may be also an initial trigger in some of the MS patients. It is also possible that these findings are not mutually exclusive, and that both the lesion location and the inflammatory process contribute to pain and migraine onset. In line with a previous study ([@bb0034]), we did not find that MS patients or HIs with and without migraine differed significantly in T2 or T1 lesion burden, although the RRMS patients with migraine in the present study showed somewhat greater T2- and T1-LVs despite shorter disease duration compared to those without migraine.

Past studies have suggested that migraine is associated with GM pathology ([@bb0035]), although these findings were based on a small number of subjects and there were other studies showing conflicting results ([@bb0036]). It has been demonstrated that migraine subjects do not present with cortical lesions ([@bb0037]). Brain volumetry findings from the current study suggest that there is no significant difference in the GM and WM in HIs, MS and CIS groups between migraine and non-migraine subjects. Furthermore we did not find a significant difference in GM volumes by MS disease subtype. In terms of overall impact on MS severity, previous studies have found no significant correlation between level of disability and the presence of headache ([@bb0010]), which was confirmed in the current study.

It has been shown that treatment of MS with interferon-beta is associated with higher rate of migraine, but this increase is mainly due to the exacerbation of preexisting migraine and is less commonly associated with the new onset ([@bb0038]; [@bb0013]; [@bb0039]). This is further supported by the fact that patients receiving interferon-beta may experience exacerbation of their migraine symptoms. As migraine may be iatrogenically triggered by use of DMT, we used treatment status, as a covariate in all our analyses. We further explored the differences between interferon-beta and other DMTs in MS patients with and without migraine (data not shown) and found no associations.

In addition, neuropathic pain is frequent in patients with MS and can be concomitantly present with migraine ([@bb0012]). In a recent study, 32% of the MS patients who presented both with migraine and neuropathic pain, had more severe pain and lower health-related quality of life than MS patients with either migraine or neuropathic pain alone ([@bb0012]). The pain intensity in MS patients with migraine was higher (6.0 ± 0.1) than that of neuropathic pain (4.9 ± 0.1). Moreover, in agreement with the present study, the migraine MS patients were younger and had more likely RRMS. This indicates that neuropathic pain and migraine pain may be mediated by different mechanisms and that optimal treatment for management of the migraine pain needs more attention at individual patient level.

There are several limitations to this study which warrant consideration. Firstly, the timeline between the presentation of migraine and imaging was not well established, therefore it was not possible to assess the correlation between MRI outcomes and frequency of migraine attacks or migraine onset. This study utilized data from an ongoing prospective study of cardiovascular, environmental and genetic risk factors in clinically stable MS patients who performed their MRI within 30 days of entering the study. However, the proximity of the MRI to the manifestation of migraine symptoms was consistent on an individual basis, as we excluded MS patients with acute headache attack at the time of MRI. Secondly, because subtype of migraine (migraine with aura, etc) is difficult to distinguish, and number of migraine attacks is difficult to capture retrospectively outside of specialty headache clinic, we focused only on collecting information about diagnosis of migraine. In addition, we did not apply most recent ICHD-3, which was not available at the time when this study was designed ([@bb0040]). Thirdly, the association of increased CE lesion activity in MS patients with migraine does not prove causation, especially because we were not able to apply a contrast agent to the HIs in this study, which prevented us to understand whether migraine subjects without MS may show signs of BBB disruption. Nevertheless, findings from current study should encourage further research using longitudinal design, to explore the occurrence of CE lesion activity in active and chronic migraine MS, CIS and RIS subjects. Fourthly, the present study did not investigate the onset of migraine symptoms by location of CE lesions and future studies should investigate this topic. Finally, we did not investigate the onset of migraine symptoms by location of CE lesions and future studies should investigate this topic.

In conclusion, MS patients with migraine had a greater CE lesion activity and this was specifically manifested in RRMS patients. Our findings suggest an increased inflammatory pathobiology in MS patients with migraine headaches requiring possibly more frequent MRIs and also more efficient anti-inflammatory treatment.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

![Representative MRI images of a 32 years old female relapsing--remitting multiple sclerosis patient with disease duration of 11 and 9 years history of migraine. On the left are displayed T1-weighted spin echo post-contrast images (after 5 min delay), in the middle are shown T1-weighted spin echo pre-contrast images and on the right are displayed representative fluid attenuation inversion recovery images. There are 3 visible contrast enhancing lesions (white arrows) in different brain lobes and hemispheres.](gr1){#f0005}

###### 

Characteristics of subjects with and without migraine in patients with multiple sclerosis and clinically isolated syndrome, and in healthy individuals.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
                                         HIs\          MS\           CIS\                                                                           
                                         (n = 251)     (n = 509)     (n = 64)                                                                       
  -------------------------------------- ------------- ------------- ---------- ------------- ------------- ----------- ------------- ------------- -----------
  Female, n (%)                          136 (63.6)    28 (75.7)     0.135      266 (67.2)    95 (84.1)     **0.01**    38 (71.7)     10 (90.1)     0.181

  Age in years, mean (SD)                43.0 (17.4)   43.6 (13.9)   0.852      46.9 (12.4)   42.4 (13.0)   **0.001**   39.9 (11.3)   38.3 (9.9)    **0.001**

  Age at onset in years, mean (SD)       NA            NA            NA         32 (10.7)     29.8 (10.5)   0.066       36.0 (11.1)   31.9 (10.5)   0.266

  Disease duration in years, mean (SD)   NA            NA            NA         15 (10.7)     12.4 (9.6)    **0.024**   1.3 (2.1)     1.4 (2.2)     0.115

  BMI, mean (SD)                         26.8 (5.5)    26.9 (5.5)    0.95       26.7 (5.5)    26.5 (5.9)    0.745       27.2 (6)      26.5 (5.5)    0.734

  Presence of DMT, n (%)                 NA            NA            NA         284 (71.7)    83 (73.5)     0.884       26 (49.1)     4 (36.3)      0.634

   Interferon-beta 1a                                                           140 (49.3)    34 (41)                   20 (76.9)     3 (75)        

   Glatiramer acetate                                                           73 (25.7)     27 (32.5)                 6 (23.1)      1 (25)        

   Natalizumab                                                                  56 (19.7)     18 (21.7)                 0 (0)         0 (0)         

   Mycophenolate mofetil                                                        6 (2.1)       1 (1.2)                   0 (0)         0 (0)         

   Intravenous immunoglobulin                                                   5 (1.8)       2 (2.4)                   0 (0)         0 (0)         

   Azathioprine                                                                 3 (1.1)       1 (1.2)                   0 (0)         0 (0)         

   Mitoxantrone                                                                 1 (0.4)       0 (0)                     0 (0)         0 (0)         

  EDSS, mean (IQR)                       NA            NA            NA         3.6 (2.2)     3.2 (1.8)     0.082       1.3 (.7)      1.9 (1.7)     0.092

  Race, n (%)                                                        0.168                                  0.337                                   

   White                                 183 (85.5)    33 (89.2)                373 (94.2)    103 (91.2)                48 (90.5)     11 (100)      0.771

   Hispanic/Latino                       2 (0.9)       1 (2.7)                  4 (1.0)       4 (3.5)                   2 (3.8)       0 (0)         

   Black/African/American                16 (7.5)      2 (5.4)                  15 (3.8)      5 (4.4)                   2 (3.8)       0 (0)         

   Asian                                 8 (3.7)       0 (0)                    2 (0.5)       0 (0)                     1 (1.9)       0 (0)         

   American Indian/Alaska native         0 (0)         1 (2.7)                  0 (0)         0 (0)                     0 (0)         0 (0)         

   Other                                 5 (2.3)       0 (0)                    2 (0.5)       1 (0.9)                   0 (0)         0 (0)         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

HIs---healthy individuals; MS---multiple sclerosis; CIS---clinically isolated syndrome; SD---standard deviation; EDSS---Expanded Disability Status Scale; DMT---disease modifying therapy; NA---not available; BMI---body mass index; IQR--- interquartile range.

The comparison between the migraine and non-migraine subjects was performed using chi-square test, Mann--Whitney rank sum test and one-way analysis of variance. p-Values \< 0.05 were considered significant (highlighted in bold).

###### 

Characteristics of subjects with and without migraine in patients with relapsing--remitting, secondary-progressive and primary-progressive multiple sclerosis.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
                                         RRMS\         SPMS\         PPMS\                                                                          
                                         (n = 320)     (n = 124)     (n = 36)                                                                       
  -------------------------------------- ------------- ------------- ----------- ------------- ------------- ----------- ------------- ------------ -----------
  Female, n (%)                          159 (78.8)    68 (86.1)     **0.001**   77 (74)       18 (90)       0.122       17 (56.7)     3 (50)       0.764

  Age in years, mean (SD)                44.6 (10.3)   42.2 (11.4)   0.081       54.7 (7.5)    49.9 (10.6)   **0.015**   56.0 (6.9)    49.3 (4.7)   **0.032**

  Age at onset in years, mean (SD)       32.3 (9.2)    30.2 (9.4)    0.082       32.4 (11.1)   29.2 (9.9)    0.22        37.9 (10.8)   42.4 (6)     0.374

  Disease duration in years, mean (SD)   12.4 (8.9)    11.4 (8.7)    0.401       22.4 (10.9)   20.7 (9.8)    0.527       18.1 (11.5)   6.8 (4.5)    **0.039**

  BMI, mean (SD)                         27.5 (5.6)    27.0 (6)      0.555       25.8 (5)      24.7 (5.7)    0.376       26.1 (4.2)    26.0 (5.6)   0.954

  Presence of DMT, n (%)                 204 (84.6)    60 (75.9)     0.579       72 (69.2)     15 (75)       0.831       13 (43.3)     3 (50)       0.85

   Interferon-beta 1a                    101 (49.5)    24 (40)                   40 (55.6)     6 (40)                    5 (38.5)      1 (33.3)     5

   Glatiramer acetate                    51 (25)       21 (35)                   14 (19.4)     5 (33.3)                  5 (38.5)      2 (66.7)     

   Natalizumab                           45 (22.1)     14 (23.3)                 12 (16.7)     2 (13.3)                  0 (0)         0 (0)        

   Mycophenolate mofetil                 3 (1.5)       0 (0)                     3 (4.2)       0 (0)                     1 (7.7)       0 (0)        

   Intravenous immunoglobulin            3 (1.5)       1 (1.7)                   1 (1.4)       1 (6.7)                   1 (7.7)       0 (0)        

   Azathioprine                          0 (0)         0 (0)                     2 (2.8)       1 (6.7)                   1 (7.7)       0 (0)        

   Mitoxantrone                          1 (0.5)       0 (0)                     0 (0)         0 (0)                     0 (0)         0 (0)        

  EDSS, mean (IQR)                       2.6 (1.5)     2.6 (1.4)     0.884       5.6 (1.5)     5.2 (1.9)     0.25        5.7 (1.9)     4.8 (1.2)    0.298

  Race, n (%)                                                        0.385                                   0.851                                  0.071

   White                                 225 (93.4)    70 (88.6)                 100 (96.1)    20 (100)                  29 (96.7)     5 (83.3)     

   Hispanic/Latino                       3 (1.2)       3 (3.8)                   1 (1.0)       0 (0)                     0 (0)         1 (16.7)     

   Black/African/American                10 (4.1)      5 (6.3)                   2 (1.9)       0 (0)                     1 (3.3)       0 (0)        

   Asian                                 2 (0.8)       0                         0             0 (0)                     0 (0)         0 (0)        

   American Indian/Alaska native         0 (0)         0                         0             0 (0)                     0 (0)         0 (0)        

   Other                                 1 (0.4)       1 (1.3)                   1 (1.0)       0 (0)                     0 (0)         0 (0)        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

MS---multiple sclerosis; RRMS---relapsing--remitting; SPMS---secondary-progressive; PPMS---primary-progressive; SD---standard deviation; EDSS---Expanded Disability Status Scale; DMT---disease modifying therapy; NA---not available; BMI---body mass index; IQR---interquartile range.

The comparison between the migraine and non-migraine groups was performed using chi-square test, Mann--Whitney rank sum test and one-way analysis of variance. p-Values \< 0.05 were considered significant (highlighted in bold).

###### 

Within study group MRI comparisons between subjects with and without migraine.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
                           HIs\            MS\             CIS\                                                                                                   
                           (n = 251)       (n = 509)       (n = 64)                                                                                               
  ------------------------ --------------- --------------- ---------- --------------------- --------------------- ----------- ----------------- ----------------- -------
  Presence of CE lesions   NA              NA              NA         94 (23.7)             40 (35.4)             **0.013**   9 (17)            2 (18.2)          0.923

  Number of CE lesions     NA              NA              NA         0.21 (0.74)           0.91 (4.36)           **0.019**   0.45 (1.25)       0.10 (0.32)       0.380

  CE-LV                    NA              NA              NA         31.2 (134.4)          125.3 (572.6)         **0.022**   65.8 (196.5)      5.4 (17.1)        0.326

  Number of T2 lesions     2.7 (6.82)      2.03 (4.5)      0.505      29 (20)               27.8 (19.8)           0.401       22.2 (25.8)       11 (6.9)          0.170

  T2-LV                    277.1 (1200)    113.5 (241.1)   0.402      13,901.7 (16,530.2)   13,546.2 (15,966.2)   0.829       4406.7 (6111.7)   1960.9 (1794.3)   0.183

  Number of T1 lesions     NA              NA              NA         11.21 (11.52)         10.12 (12.33)         0.412       4.14 (7.83)       2.70 (4.88)       0.469

  T1-LV                    NA              NA              NA         3021.6 (5528.6)       3082.4 (7479.1)       0.832       423.6 (731.8)     369.3 (957.9)     0.706

  NBV                      1533.8 (95.3)   1551.9 (83)     0.089      1474.5 (99.1)         1484.9 (95.6)         0.278       1543.4 (63.7)     1580 (81.3)       0.157

  NGMV                     780.2 (67.2)    789.9 (52.7)    0.191      734.4 (71.9)          747.4 (68.2)          0.651       784 (49)          802.3 (59.9)      0.444

  NWMV                     753.6 (44.1)    762.1 (44.1)    0.156      740.1 (66.8)          737.5 (65)            0.332       759.4 (44.1)      777.7 (70.6)      0.278

  NLVV                     34.3 (15.5)     30.2 (9.2)      0.107      49.6 (22.6)           46 (22.1)             0.954       35.2 (12.7)       33.9 (19.2)       0.999

  NCV                      636.1 (57.4)    644.3 (46.3)    0.231      594.3 (60.7)          607.1 (56.9)          0.819       633.4 (40.5)      658.6 (47.7)      0.115
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

HIs---healthy individuals; MS---multiple sclerosis; CIS---clinically isolated syndrome; CE---contrast enhancing; LV---lesion volume; NA---not available; NBV---normalized brain volume; NGMV---normalized gray matter volume; NWMV---normalized white matter volume; NLVV---normalized lateral ventricular volume; NCV---normalized neocortical volume.

All data are presented as mean and standard deviations. The presence of CE is reported as the number and percentage. Volumetric measures are presented in cubic millimeters (mm^3^) for LV and in cubic centimeters (cm^3^) for brain volumes.

The comparison between HIs, MS and CIS groups was performed using analysis of covariance with age, gender and disease-modifying treatment, as covariates. p-Values \< 0.05 were considered significant (highlighted in bold) after correction for multiple comparisons.

###### 

Within disease course MRI comparisons between subjects with and without migraine.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                           RRMS\                 SPMS\               PPMS\                                                                                                       
                           (n = 320)             (n = 124)           (n = 36)                                                                                                    
  ------------------------ --------------------- ------------------- ----------- --------------------- --------------------- ------- --------------------- --------------------- -------
  Presence of CE lesions   68 (28.2)             33 (41.8)           **0.035**   26 (25)               7 (35)                0.354   0 (0)                 0 (0)                 NA

  Number of CE lesions     0.3 (0.84)            1.19 (4.9)          **0.023**   0.07 (.3)             0 (0)                 0.224   0 (0)                 0 (0)                 0.806

  CE-LV                    41.1 (144.4)          164.4 (651.9)       **0.02**    6.1 (28.6)            0 (0)                 0.324   1.6 (8.5)             0 (0)                 0.806

  Number of T2 lesions     27.1 (19.3)           28.2 (17.9)         0.951       33.8 (19.7)           29.4 (24.1)           0.241   31.8 (24.4)           15.3 (11.7)           0.081

  T2-LV                    11,421.3 (14,030.7)   12,163.3 (14,300)   0.732       19,357.2 (17,541.4)   19,850.3 (20,378.2)   0.701   17,256.3 (19,859.5)   10,457.4 (12,508.5)   0.413

  Number of T1 lesions     10.1 (10.8)           9.7 (11.9)          0.638       15.1 (12.3)           12.4 (14.1)           0.352   11.6 (12.7)           11.3 (10.4)           0.98

  T1-LV                    2424.2 (4769.6)       3020.2 (8106.5)     0.417       5050.6 (7378.7)       4338.9 (6419.1)       0.580   2236.3 (2554.0)       2015.9 (2725.2)       0.850

  NBV                      1492.8 (88.5)         1488.8 (96.5)       0.187       1414.7 (77.4)         1428.5 (70.7)         0.832   1430.9 (93.9)         1485.9 (60.8)         0.688

  NGMV                     742.5 (66.3)          748.9 (64.7)        0.747       697.5 (58.9)          710 (54.5)            0.59    715.7 (48.4)          732.3 (57.5)          0.521

  NWMV                     750.3 (60.9)          740 (67.2)          0.144       717.2 (71.6)          718.6 (61.2)          0.825   715.3 (71.3)          753.6 (76.2)          0.423

  NLVV                     45.8 (20.1)           45.6 (22.8)         0.402       60.3 (22.7)           54.2 (23.6)           0.353   57 (26.8)             43 (8.8)              0.494

  NCV                      600.1 (55.5)          609.8 (52.7)        0.822       564.6 (50.9)          570 (41.8)            0.903   580.4 (41.9)          593.4 (55.3)          0.619
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MS---multiple sclerosis; RRMS---relapsing--remitting; SPMS---secondary-progressive; PPMS---primary-progressive; SD---standard deviation; CE---contrast enhancing; LV---lesion volume; NA---not available; NBV---normalized brain volume; NGMV---normalized gray matter volume; NWMV---normalized white matter volume; NLVV---normalized lateral ventricular volume; NCV---normalized neocortical volume.

All data are presented as mean and standard deviations. The presence of CE is reported as the number and percentage. Volumetric calculations are presented in cubic millimeters (mm^3^) for LV and in cubic centimeters (cm^3^) for brain volumes.

The comparison between RRMS, SPMS and PPMS groups was performed using analysis of covariance with age, gender and disease-modifying treatment, as covariates. p-Values \< 0.05 were considered significant (highlighted in bold) after correction for multiple comparisons.
